REVB
REVELATION BIOSCIENCES, INC.
Next earnings Aug 6, 2026 · consensus $-0.85 EPS
Last earnings +0.0% on 2026-05-07
$1.08
▲ +3.85%$1.08▼ -88.14%
over 1Y
L $0.96H $12.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.8%
1W+12.5%
1M+1.9%
3M-13.6%
YTD-66.8%
1Y-88.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.31x).
Return on equity -100.6% · latest
REVELATION BIOSCIENCES, INC. shows limited reported revenue, and -100.6% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.31x).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.0M | -$10.9M | -$8.66M | -$7.98M | -$9.07M |
| Net income | -$12.0M | -$10.8M | -$120K | -$15.0M | -$8.91M |
| Diluted EPS | -$42.50 | -$149.20 | -$8.44 | -$1,052.16 | -$23.95 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$6.48M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-211.2%
FCF yield-196.4%
Quality & risk
ROIC (est.)-80.9%
Free cash flow-$8.29M
Total debt—
Net cash$10.7M
Piotroski F-Score3/6
Capital returns
Buyback yield841.0%
Dividend yield (est.)—
Shareholder yield841.0%
Shares Δ YoY+311.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-24open ↗8-KPeriod ending 2026-06-012026-06-01open ↗SCHEDULE 13GFiling2026-05-15open ↗DEF 14APeriod ending 2026-06-242026-05-11open ↗ARSPeriod ending 2026-05-112026-05-11open ↗8-KPeriod ending 2026-05-072026-05-07open ↗10-QPeriod ending 2026-03-312026-05-07open ↗4Period ending 2026-04-302026-05-01open ↗4Period ending 2026-04-302026-05-01open ↗PRE 14APeriod ending 2026-06-242026-04-30open ↗S-8Filing2026-04-15open ↗8-KPeriod ending 2026-03-182026-03-19open ↗
Frequently asked
- Is REVELATION BIOSCIENCES, INC. (REVB) a buy?
- REVB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.31x).
- What is REVELATION BIOSCIENCES, INC.'s quality score?
- REVB scores 52.67181174089069/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001810560, latest 10-Q filed 2026-05-07) · EODHD · as of 7/4/2026, 12:52:26 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.